Recombinant factor VIIa for unlicensed indications--a definite No or a cautious Maybe in selected patients?
Sorour
Y
Y
Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK.
Van Veen
J J
JJ
Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK.
Makris
M
M
Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK.
D016638:Critical Illness; D004630:Emergencies; D015942:Factor VIIa / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000517:prevention & control*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D056687:Off-Label Use; D018579:Patient Selection; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D013927:Thrombosis / Q000139:chemically induced
D006490:Hemostatics; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa